Jazz Pharmaceuticals delivered a first quarter that was met with a positive response from the market, driven largely by strong commercial execution across its sleep, epilepsy, and oncology franchises. Management credited the performance to robust demand for Xywav, Epidiolex, Midevo, and Zepzelca, with CEO Renée Galá highlighting, “Our commercial teams generated double-digit growth across all our promoted brands, and saw strong contributions from our ongoing launches.” The company’s focus on differentiated patient support and broadening market penetration for both new and established therapies contributed to the notable revenue growth observed this quarter.
Is now the time to buy JAZZ? Find out in our full research report (it’s free for active Edge members).
Jazz Pharmaceuticals (JAZZ) Q1 CY2026 Highlights:
- Revenue: $1.07 billion vs analyst estimates of $977.1 million (19.1% year-on-year growth, 9.4% beat)
- Adjusted EPS: $6.34 vs analyst estimates of $4.66 (36.2% beat)
- Adjusted EBITDA: $507.2 million vs analyst estimates of $393.3 million (47.5% margin, 29% beat)
- The company reconfirmed its revenue guidance for the full year of $4.38 billion at the midpoint
- Operating Margin: 31.5%, up from -6.2% in the same quarter last year
- Market Capitalization: $14.03 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Jazz Pharmaceuticals’s Q1 Earnings Call
- Jessica Macomber Fye (JPMorgan) asked about the sequencing and positioning of zanidatumab in breast cancer post-ENHERTU. Chief Medical Officer Robert Iannone explained their trial is designed to provide definitive data, aiming to inform physician decisions in a space with little available evidence after ENHERTU.
- Joseph John-Charles Thome (TD Cowen) inquired about the addressable patient population for Midevo and the company’s M&A strategy. Chief Commercial Officer Samantha Pearce discussed longer-than-expected treatment durations and potential population upside, while CEO Renée Galá emphasized a focus on rare disease expansion and financial readiness to pursue deals.
- Leonid Timashev (RBC) asked about Jazz Pharmaceuticals’ approach to epilepsy market expansion and potential cannibalization. Galá cited persistent unmet need, the durability of Epidiolex’s franchise, and ongoing investment in both pipeline and business development to address multiple treatment pathways.
- Annabel Samimy (Stifel) probed the impact of moving Midevo into first-line therapy. Pearce and Iannone explained that earlier use could increase eligible patients and extend treatment duration, supporting the company’s peak sales assumptions for the drug.
- Marc Goodman (Leerink) questioned international Epidiolex growth drivers and Rylaze’s quarterly performance. Pearce highlighted execution in Europe and the UK’s pricing adjustment, while noting that Rylaze’s growth this quarter is expected to stabilize going forward.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will monitor (1) the timing and outcome of the FDA's decision on ZYHERA for gastric cancer, (2) interim and top-line readouts from pivotal studies for Midevo and zanidatumab, and (3) the competitive landscape’s impact on the sleep franchise as generics and new therapies increase their market presence. Continued execution in business development and the ability to expand into new rare disease areas will also be key indicators of progress.
Jazz Pharmaceuticals currently trades at $224.30, up from $212.26 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
